| Outcome Measures: |
Primary: Changes in pulmonary function parameters, The primary endpoints were the between-group differences in the changes in pulmonary function parameters between pretherapy and posttreatment, 26 weeks | Secondary: Changes in glycosylated hemoglobinA1c, fasting plasma glucose, 2-hour postprandial blood glucose,, The secondary endpoints were changes from baseline to week 26 in glycosylated hemoglobinA1c, fasting plasma glucose, 2-hour postprandial blood glucose,. The tertiary endpoints were the changes from baseline to week 26 in blood-fat, 26 weeks | Other: Changes in blood-fat in Systolic blood pressure,Diastolic blood pressure, and blood-fat, The quartus endpoints were the changes from baseline to week 26 in Systolic blood pressure,Diastolic blood pressure, and blood-fat, 26 weeks|Changes in retrobulbar hemodynamics (RI), The fifth endpoints were the changes from baseline to week 26 in retrobulbar hemodynamics (RI) in the bilateral central retinal artery,posterior ciliary artery, endarteria ophthalmica., 26 weeks
|
